Shares of Neurotrope Inc (NASDAQ:NTRP) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $15.00 for the company and are expecting that the company will post ($0.38) earnings per share for the current quarter, according to Zacks. Zacks has also given Neurotrope an industry rank of 63 out of 256 based on the ratings given to its competitors.
Separately, Janney Montgomery Scott assumed coverage on Neurotrope in a research report on Tuesday, June 18th. They set a “buy” rating and a $14.00 target price for the company.
Shares of Neurotrope stock opened at $5.23 on Wednesday. The company has a 50 day moving average price of $6.91. Neurotrope has a 52-week low of $3.33 and a 52-week high of $10.50.
Neurotrope (NASDAQ:NTRP) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter. Equities analysts expect that Neurotrope will post -1.56 earnings per share for the current year.
A hedge fund recently bought a new stake in Neurotrope stock. Raymond James & Associates purchased a new stake in Neurotrope Inc (NASDAQ:NTRP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,823 shares of the company’s stock, valued at approximately $42,000. Raymond James & Associates owned approximately 0.15% of Neurotrope as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.82% of the company’s stock.
Neurotrope Company Profile
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Read More: What does it mean to hold a stock in street name?
Get a free copy of the Zacks research report on Neurotrope (NTRP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.